STRL's Backlog Strength Meets Valuation Ceiling

What happened

A recent Zacks article highlights Sterling Infrastructure's growing backlog visibility as a key driver for 2026-2027 growth, emphasizing the conversion of mission-critical demand into deeper project pipelines. However, the DeepValue master report rates STRL a Potential Sell at $372.25, citing a 36x P/E and 25x EV/EBITDA that already price in sustained mid-20s margins and robust AI data-center spending. While the backlog expansion is real, nearly a third of the $3.44B combined backlog comes from acquisitions and unsigned awards, and E-Infrastructure margins are vulnerable to mix shifts and project delays. The bull case of persistent high-20s margins offers only ~16% upside to $430, while the bear case of normalization to 22% margins implies ~30% downside to $260. At current levels, the risk-reward is unfavorable, and the favorable narrative around backlog visibility masks elevated valuation and execution risk.

Implication

Investors should view the backlog visibility narrative with caution; the premium multiple leaves little room for error, and any sign of margin compression or AI capex slowdown could trigger a re-rating. Our base case fair value of $340 sits below the current price, and we recommend trimming on strength and waiting for a pullback toward $320 before considering a position. The next key catalyst is Q4 2025 earnings and 2026 guidance, particularly any guidance for E-Infrastructure margins below 24%, which would break the thesis. Given the crowded bullish consensus, the stock is susceptible to sharp drawdowns if hyperscaler capex expectations moderate. A disciplined exit above $400 and re-entry near $320 provides a better risk-reward profile.

Thesis delta

The Zacks article reinforces the bullish narrative around backlog visibility, but our report shows that the current stock price already embeds aggressive assumptions for margin sustainability and AI capex growth. The thesis shifts from 'backlog drives upside' to 'backlog is necessary but insufficient to justify valuation' — at $372, the risk-reward skews negative, and we see limited upside given the premium multiple and concentration risk.